Laurie H. Glimcher, MD
President and Chief Executive Officer
Laurie H. Glimcher, MD, is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and
Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.
Dr. Glimcher is a Member of the National Academy of Sciences, Fellow of the American Academy of Arts and Sciences, a Member of the American Philosophical Society, a Member of the National Academy of Medicine, and the former President of the American Association
of Immunologists. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics and Kaleido BioSciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, the
American Association for Cancer Research, the Association of American Cancer Institutes, and the American Society of Clinical Oncology, and served on the Vice President's Blue Ribbon panel. She previously served on the Board of Directors of Bristol-Myers
Squibb Pharmaceutical Corporation and the Waters Corporation. She currently serves on the Board of Directors of GlaxoSmithKline Pharmaceutical Corporation and Analog Devices, Inc.
A trailblazer in cancer research, Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks
nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.
Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women
in science. Notably, she was the first female to be appointed as Dean of Weill Cornell Medicine in New York, and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute.
Dr. Glimcher is the recipient of many awards and honors. In 2018, she received the American Association of Immunologists Lifetime Achievement Award; the Indiana University School of Medicine's Steven C. Beering Award for outstanding research contributions
to the advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M. Kober Medal and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association
of American Medical Colleges (AAMC).
Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.
Learn more about Laurie Glimcher, MD
William C. Hahn, MD, PhD
Interim Executive Vice President and Chief Operating Officer
Chief Scientific Officer
Chair, Executive Committee for Research (ECR)
William C. Hahn, MD, PhD, has been engaged in clinical care and research at Dana-Farber since 1996. He is the William Rosenberg Professor of Medicine and an Institute Member of the Broad Institute of MIT and
Harvard. He received his AB in Biochemical Sciences, PhD in Immunology, and MD all from Harvard University and completed his clinical training at Massachusetts General Hospital and Dana-Farber Cancer Institute. His research focuses on understanding
how mutations cooperate in cancer initiation and progression to develop rational combination therapies.
Scott A. Armstrong, MD, PhD
President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Chair, Department of Pediatric Oncology
Scott A. Armstrong, MD, PhD, is president of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute; and the David G. Nathan Professor of Pediatrics. He also serves
as associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Dr. Armstrong was previously director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weill
Cornell Medical College. He earned his medical degree and PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston
Children’s Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
The major focus of Dr. Armstrong’s career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and
the relationship between leukemia and normal hematopoietic stem cells. Dr. Armstrong continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin-based mechanisms, and he is actively involved
in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.
Richard S. Boskey
Senior Vice President and General Counsel
Richard S. Boskey joined the Institute in 1999. He serves as assistant secretary of Dana-Farber Cancer Institute and Dana-Farber/Partners CancerCare, and secretary of the Dana-Farber Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care. Previously,
he served in various positions at Partners HealthCare and Massachusetts General Hospital, including deputy general counsel, and was an associate at the law firm Hill & Barlow. Mr. Boskey received his bachelor's degree from Brown University and his
master's and law degrees from the University of Virginia.
Craig A. Bunnell, MD, MPH, MBA
Chief Medical Officer
Craig A. Bunnell, MD, MPH, MBA, became the chief medical officer and medical director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College
after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts
Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as chief medical resident. Dr. Bunnell is a medical oncologist involved in research
and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
Kathleen Burns, MD, PhD
Chair, Department of Oncologic Pathology
Kathleen Burns, MD, PhD, joined Dana-Farber in 2020 as the Chair of Oncologic Pathology. She received her MD and PhD degrees from Baylor College of Medicine, and was recruited to Johns Hopkins University School of Medicine for clinical pathology residency
and hematopathology fellowship. Thereafter, she joined the faculty at Johns Hopkins, progressed through their academic ranks to Professor, and served as the pathology department's Deputy Director (Vice Chair) for Research and Director of the institution's
Physician Scientist Training Program (PSTP). Dr. Burns's research focuses on high copy number genomic repeats and transposable elements, their contributions to human disease, and ways to leverage our understanding of their biology to treat cancers.
Michelle Cox
Senior Vice President for Research Operations
Michelle Cox joined Dana-Farber upon graduation from Assumption College in 1992. Michelle is the Senior Vice President for Research Operations. Prior to this role, she served as the Department Administrator for Pediatric Oncology for over 15 years before
transitioning into Research Administration, where she held the positions of Senior Director for Shared Resources for Dana-Farber/Harvard Cancer Center and Vice President of Research Operations.
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
George D. Demetri, MD, advances institutional efforts in the discovery and development of novel anticancer therapies based on experience gained from his leadership in several drug development efforts, including
imatinib (Gleevec) in patients with the sarcoma known as gastrointestinal stromal tumor (GIST), one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor.
Dr. Demetri's role at Dana-Farber is also complemented by serving as the co-director of the Ludwig Center at Harvard along with Joan Brugge, PhD, of Harvard Medical School, comprising more than 30 investigative teams collaborating across Harvard-affiliated
institutions to understand, overcome and prevent resistance of cancers to therapeutic interventions. Dr. Demetri trained at Harvard College and Stanford University School of Medicine, followed by internal medicine residency and chief residency at
the University of Washington Hospitals in Seattle. He also co-directs the Harvard Medical School Global Education course on Cancer Biology and Therapeutics.
Lisa R. Diller, MD
Chief Medical Officer, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Lisa R. Diller, MD, chief medical officer at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is also the clinical director of Pediatric Oncology, and the medical director of the David B. Perini,
Jr. Quality of Life Clinic. Her research focuses on the late effects of treatment of childhood cancer and genetic cancer predispositions in childhood; her clinical work focuses on pediatric solid tumors. Dr. Diller received her bachelor’s degree from
Harvard University and earned her Doctor of Medicine from the University of California at San Diego.
Gerard M. Doherty, MD
Chair of Surgery
A graduate of College of the Holy Cross and Yale School of Medicine,
Gerard M. Doherty, MD, completed residency training at UCSF, including a fellowship at the National Cancer Institute. He joined Washington University School of Medicine in 1993, and became professor of
Surgery in 2001. In 2002 he was named head of General Surgery and Thompson Professor of Surgery at the University of Michigan, where he also served as General Surgery Program director and vice chair of the Department of Surgery. From 2012 to 2016,
Dr. Doherty was Utley Professor and Chair of Surgery at Boston University and surgeon-in-chief at Boston Medical Center, before becoming professor of Surgery at Harvard Medical School, and surgeon-in-chief at Brigham and Women’s Hospital.
Dr. Doherty has focused on surgical diseases of the thyroid, parathyroid, endocrine, pancreas, and adrenal glands, as well as the surgical management of MEN syndromes. He has devoted substantial effort to medical student and resident education policy.
His bibliography includes over 300 peer-reviewed articles, reviews, and book chapters, and several edited books.
He currently serves as president-elect of the International Association of Endocrine Surgeons, past-president of the American Association of Endocrine Surgeons, member of the Surgical Oncology Board of the American Board of Surgery (ABS), editor-in-chief
of VideoEndocrinology, and reviews editor of JAMA Surgery.
Melany Duval
Senior Vice President, Chief Philanthropy Officer
Melany Duval joined Dana-Farber in 2019. Prior to this, she was Vice President of Development at Silicon Valley Community Foundation, the largest community foundation in the world. She also held positions as Senior Associate Dean and Associate Vice President
of Health Science Campus Development at the University of Southern California, and at Children’s Hospital of Los Angeles. Ms. Duval earned her bachelor’s degree in political science and business administration from Loyola Marymount University.
Benjamin Ebert, MD, PhD
Chair of Medical Oncology
Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber Cancer Institute, is professor of Medicine at Harvard Medical School, an institute member of the Broad Institute, and leader of the Leukemia
Program for the Dana-Farber/Harvard Cancer Center.
His research focuses on the genetics, biology, and therapy of myeloid malignancies. This work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of
lenalidomide and related molecules that induce degradation of specific proteins.
Dr. Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an MD from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship
in hematology/oncology at Dana-Farber.
Ildemaro Gonzalez
Vice President and Chief Inclusion & Diversity Officer
Ildemaro Gonzalez joined Dana-Farber in 2019. He is a diversity and inclusion (D&I) leader with a successful 20-year track record designing and implementing innovative D&I strategies. In a domestic and global context, he works to align D&I with the strategic
priorities of the organization and impact all aspects of the operation, including both employee and patient experiences.
Mr. Gonzalez has served as Chief Inclusion and Diversity Officer at Parkland Health and Hospital System; Global Director of Inclusion and Philanthropy at Newell Rubbermaid; and Managing Director, Diversity Strategy at the American Cancer Society-National
Home Office. He galvanized executives and board members around a common vision; leveraged partnerships with operational leaders for long term adoption of new D&I initiatives; and engaged employees in driving diversity, inclusion, and engagement outcomes.
He earned an MBA from Georgia State University, and a BBA from the Universidad Catolica Andres Bello, in Caracas, Venezuela.
Anne Gross, PhD, RN, NEA-BC, FAAN
Senior Vice President, Patient Care Services and Chief Nursing Officer
Anne Gross, PhD, RN, NEA-BC, FAAN, became Dana-Farber’s senior vice president for patient care services and chief nursing officer in 2016. She joined Dana-Farber in 2002 and since 2004 served as vice president, Adult Nursing and Clinical Services. Dr.
Gross is a Fellow of the American Academy of Nursing and currently serves as co-chair elect of the Academy’s Fellows Selection Committee. Prior to joining Dana-Farber, she was a clinical nurse and leader, most recently at Cambridge Health Alliance.
She received her bachelor's degree in nursing from St. Louis University, her master’s degree in nursing from Boston College, and her doctoral degree from the University of Massachusetts.
Daphne Haas-Kogan, MD
Professor and Chair, Department of Radiation Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Boston Children’s Hospital
Daphne Haas-Kogan, MD, received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology at the
UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). Dr. Haas-Kogan spent 18 years as a radiation oncologist, researcher, and academic leader in the UCSF HDFCCC system before becoming chair of the Department of Radiation Oncology at Dana-Farber,
Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.
Kevin M. Haigis, PhD
Chief Research Officer
Kevin M. Haigis, PhD, joined Dana-Farber as Chief Research Officer in 2020. Prior to assuming this role, Dr. Haigis was Director of Cancer Genetics at Beth Israel Deaconess Cancer Center. Dr. Haigis received his PhD in genetics from the University of
Wisconsin-Madison and did post-doctoral work at the Massachusetts Institute of Technology, where he was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation.
Dr. Haigis has a long-standing interest in intestinal biology and the molecular pathogenesis of colorectal cancer. His laboratory combines computational and informatic approaches with experimental approaches in genetically engineered mice to study the
relationship among Ras oncogene signaling, colorectal cancer, and inflammation.
Bruce E. Johnson, MD
Chief Clinical Research Officer
Bruce E. Johnson, MD, became Dana-Farber’s chief clinical research officer in 2013. He previously was director of the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center. He
is also professor of Medicine at Harvard Medical School and an American Society of Clinical Oncology translational research professor. Dr. Johnson is serving as the interim director of the Center for Cancer Precision Medicine (CCPM).
Dr. Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute. In 1992, he became head of the Lung Cancer
Biology Section, Medicine Branch, at the NCI, until 1998, when he joined Dana-Farber. Dr. Johnson is currently serving as president of the American Society of Clinical Oncology.
Dr. Johnson directs the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic
changes.
Jason M. Johnson, PhD
Chief Health Information Officer
Jason M. Johnson, PhD, joined the Institute in April 2016 and serves as chief health information officer. Prior to joining Dana-Farber, Dr. Johnson was executive vice president and head of R&D at PatientsLikeMe, a patient-focused research company in Cambridge,
MA. He came to that position after serving in various leadership roles in scientific informatics, bioinformatics, and genomics at Merck for many years. Dr. Johnson holds AB and BS degrees from Stanford University, a master’s degree from the University
of Cambridge (UK), and a PhD in Biophysics from Harvard University.
Elizabeth A. Liebow
Senior Vice President, Chief Strategy Officer
Elizabeth A. Liebow is the Chief Strategy Officer and Senior Vice President, Strategy and Organizational Effectiveness. Ms. Liebow is responsible for aligning the Institute’s strategy, annual goal setting, and resource planning processes. She is also
responsible for market intelligence, enterprise project management, performance improvement, and systems engineering.
In her previous role as the Senior Vice President of Clinical Planning and Business Development, Ms. Liebow directed the expansion of clinical services beyond the main Longwood campus, including the development of seven new satellite clinics sites; developed
new partnerships with six community sites and academic health centers throughout New England; and supported clinical growth and new services on Dana-Farber’s main campus.
Before joining Dana-Farber in 2004, Ms. Liebow was the Director of Business Development at Partners HealthCare, the parent organization of Brigham and Women’s Hospital and Massachusetts General Hospital, where she developed its Oncology service line.
Previous positions include Director of Community Health Center Affiliations for Partners HealthCare and Administrative Director of Children’s Services at Boston Medical Center.
Ms. Liebow holds a Master of Science degree in Health Policy and Management from the Harvard T.H. Chan School of Public Health and a BA in Economics from Brandeis University.
Kate McDaniel
Senior Vice President and Chief People Officer
As Senior Vice President and Chief People Officer, Kate McDaniel brings over 25 years of progressive human resources experience to Dana-Farber. She joins the Institute from Harvard Medical School (HMS), where she was the Chief Human Resources Officer.
While at HMS, Kate led her team in supporting a diverse population of approximately 1,600 staff, postdoctoral researchers, associates, and research associates.
Prior to joining HMS, Kate served as Senior Vice President of Human Resources at Fidelity Investments. While there, she was accountable for a national workforce of over 10,000 associates and for developing and implementing an integrated HR strategy to
attract, develop, and retain talent, transform business through organizational design, and promote engagement. Kate served as Chief Human Resources Officer and Executive Vice President at Haemonetics from 2013-2014, and was World-Wide Vice President
of Human Resources at Johnson & Johnson from 2004-2013. She holds a Bachelors of Arts degree in Industrial Relations from Lemoyne College.
Maria Megdal
Senior Vice President, Operations
Maria Megdal joined Dana-Farber Cancer Institute as the vice president for facilities management and real estate in 2008 and was named senior vice president for Institute operations in 2012.
Before joining Dana-Farber, Ms. Megdal served as vice president for corporate real estate services at Saint Vincent Catholic Medical Centers of New York. Prior to Saint Vincent's, Ms. Megdal held various management roles at Memorial Sloan-Kettering Cancer
Center after completing her administrative residency there.
Ms. Megdal holds a masters in health administration from Cornell University and a bachelors degree in physical anthropology from Rutgers University. She is a longtime member of several alumni boards at Cornell where she serves as adjunct lecturer on facilities
planning.
Drew Memmott
Senior Vice President for Cancer Center Administration
Associate Director for Administration, Dana-Farber/Harvard Cancer Center
Drew Memmott joined Dana-Farber in 2014 as the senior vice president for research administration and the associate director for administration for the Dana-Farber/Harvard Cancer Center. Prior to joining Dana-Farber, Mr. Memmott served as the associate
director for administration for the Mayo Clinic Cancer Center and as a director for research administration at Columbia University Medical Center. Mr. Memmott received his bachelor's degree from the University of Utah and graduate degrees from the
University of Washington and Columbia University.
Lee M. Nadler, MD
Senior Vice President, Experimental Medicine
Lee M. Nadler, MD, received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology,
he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department of Adult Oncology.
Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan-Mass Challenge Chair at Dana-Farber.
Michael L. Reney
Senior Vice President for Finance and Chief Financial Officer
Michael Reney joined Dana-Farber in 2015, and is responsible for treasury, accounting, business planning, revenue cycle, payer contracting, decision support, and population management. Mr. Reney also serves as Assistant Treasurer, Dana-Farber Cancer Institute,
Inc.; Assistant Treasurer, Dana-Farber, Inc.; Treasurer, The Dana-Farber Trust; and Treasurer, Dana-Farber Community Cancer Care Network. Prior to joining Dana-Farber, he served as Chief Financial Officer at Brigham and Women’s Hospital (BWH). Mr.
Reney began his career as a senior auditor at Deloitte & Touche, LLP, after which he joined BWH as its accounting manager. His extensive experience includes serving as assistant controller at Massachusetts General Hospital, followed by several positions
within Partners Healthcare. In 2000, he returned to BWH as controller and executive director of Finance, and was named Senior Vice President for Finance and Chief Financial Officer for BWHC in 2008.
Mr. Reney holds a Bachelor’s in Accounting from Bentley College and a Master’s in Business Administration from the University of Massachusetts, Boston. He is a member of the Healthcare Financial Management Association, as well as the Healthcare Roundtable
for CFOs. Additionally, he serves on the boards of the Medical Academic and Scientific Community Organization (MASCO) and Controlled Risk Insurance Company (CRICO).
Barrett J. Rollins, MD, PhD
Linde Family Professor of Medicine, Harvard Medical School
Barrett J. Rollins, MD, PhD, received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel
Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins served as Dana-Farber's Chief Scientific Officer from 2004-2019; he is currently Professor
of Medicine at Harvard Medical School and a senior advisor to Dana-Farber's President and CEO.
Stephen E. Sallan, MD
Chief of Staff Emeritus
Stephen E. Sallan, MD, joined the institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medical Staff
Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick Family
Senior Investigator in 2002.
Atul Shinagare, MD
Interim Chair, Department of Imaging
Atul Shinagare, MD, has been part of the radiology team at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) since July 2009. He is fellowship-trained in cancer imaging, abdominal imaging, and informatics, and his areas of clinical and research interests include genitourinary cancers and improving the quality of radiology reports. Dr. Shinagare is a prolific researcher with an extensive track record of high-impact publications, mentorship skills, and collaborations both within and beyond DF/BWCC. He has served as Dana-Farber's Radiology Quality and Safety Officer and Associate Program Director of the Cancer Imaging fellowship program. Currently he is associate professor of Radiology at Harvard Medical School.
Dr. Shinagare has received numerous awards, including the Radiological Society of North America (RSNA) Honored Educator award and the RSNA Research Scholar grant. He is the fellow of the Society of Abdominal Radiology, serves as associate editor for Abdominal Radiology, and is the section editor for Cancer Imaging.
Steven R. Singer
Senior Vice President for Communications
Steven R. Singer joined the Institute in 1997. He previously served as director of Communications and Public Affairs and adjunct lecturer at Harvard University's John F. Kennedy School of Government. He has worked as a press secretary in the U.S. House
of Representatives, and is past chair of the National Cancer Institute's Public Affairs Network. Mr. Singer received his bachelor's degree from Colby College and a master's degree in public administration from Harvard University's Kennedy School.
Robert J. Soiffer, MD
Chair, Executive Committee for Clinical Programs (ECCP)
Robert J. Soiffer, MD, is professor of Medicine at Harvard Medical School and institute physician at Dana-Farber. He is chief of the Division of Hematologic Malignancies, vice-chairman of Medical Oncology,
and co-director of the Bone Marrow Transplant Service at Dana-Farber. He serves on the Executive Committee for Clinical Practice, the Executive Committee for Clinical Research, and the Executive Patient Safety Oversight Group at Dana-Farber.
Dr. Soiffer is a former president of the American Society for Blood and Marrow Transplantation. He served on the advisory board for the Center for International Blood and Marrow Transplant Research. He is a member of the executive steering committees
for the Blood and Marrow Transplant Clinical Trials Network; serves on the board of directors for the National Marrow Donor Program Be the Match Registry; and serves on the board of the Massachusetts chapter of the Leukemia & Lymphoma Society.
Lesley Solomon
Senior Vice President and Chief Innovation Officer
Lesley Solomon became Dana-Farber's senior vice president and chief innovation officer in 2017. She has served as the founding executive director of Brigham and Women’s Hospital's Innovation Hub, and as director of strategy and innovation in the Brigham
Research Institute.
Ms. Solomon has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA
from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of Harvard and MIT, which brings together experts across disciplines to unlock the biology
of food allergy and change the field to develop new treatments and more.
Richard Stone, MD
Chief of Staff
Professor of Medicine, Harvard Medical School
Richard Stone, MD, is director of Dana-Farber's Adult Acute Leukemia Program. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including
acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (MDS), a bone marrow failure state that may convert to leukemia.
In addition to his work at Dana-Farber, Dr. Stone serves as chair of the Medical Oncology Board of the American Board of Internal Medicine, chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and chairman of the
Leukemia Core Committee for the Alliance for clinical Trials in Oncology.
Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women's Hospital and his hematology-oncology fellowship at Dana-Farber.
Mary-Ellen Taplin, MD
Chair, Executive Committee for Clinical Research (ECCR)
Mary-Ellen Taplin, MD, joined the Institute in 2003. She serves as director of clinical research for the Lank Center for Genitourinary Oncology at Dana-Farber /Brigham and Women’s Cancer Center. She is also
professor of Medicine at Harvard Medical School. She is an investigator on many projects, including the Prostate Cancer Clinical Trial Consortium, Dana-Farber SPORE grant, Stand Up 2 Cancer, and several Prostate Cancer Foundation Challenge Grants.
Dr. Taplin has been dedicated to clinical and translational investigations that focus on novel approaches to treating localized high risk prostate cancer and secondary hormone therapy for metastatic castration-resistant prostate cancer. She has described
molecular and physiologic alterations in the androgen receptor pathway in the context of prostate cancer resistance. Dr. Taplin is dedicated to patient care and clinical investigation in genitourinary oncology.
James Tulsky, MD
Chair, Department of Psychosocial Oncology and Palliative Care
James Tulsky, MD, received his AB from Cornell University, his MD from the University of Illinois College of Medicine at Chicago, and completed internal medicine training at the University of California, San
Francisco (UCSF). He continued at UCSF as chief medical resident and subsequently as a Robert Wood Johnson Clinical Scholar. Dr. Tulsky was on the faculty of Duke University from 1993-2015, lastly as professor of Medicine and Nursing and chief, Duke
Palliative Care. He joined Dana-Farber Cancer Institute in 2015 to be Chair, Department of Psychosocial Oncology and Palliative Care. Dr. Tulsky has a longstanding research interest in clinician-patient communication and quality of life in serious
illness.
David A. Williams, MD
Associate Chair, Department of Pediatric Oncology
David A. Williams, MD, is chief of Hematology/Oncology and director of Clinical and Translational Research at Boston Children’s Hospital and associate chairman, Department of Pediatric Oncology at Dana-Farber
Cancer Institute. He is director of the Pediatric Hematology/Oncology Fellowship Training Program at Dana-Farber/Boston Children's.
Dr. Williams' laboratory has been continuously NIH-funded since 1986. He has served on multiple NIH Study Sections, including currently on the Loan Repayment Study Section for Pediatrics; he served for five years on the NCI Parent Committee for Comprehensive
Cancer Centers. Dr. Williams served on both the Recombinant DNA Advisory Committee (RAC) and the NIH Gene Therapy Safety Advisory Board. He is a past President of the American Society of Hematology. He has trained over 45 fellows and post-doctoral
fellows and numerous residents and medical students in his laboratory, the majority of whom are still in academic medicine.
Dr. Williams is a member of the National Academy of Sciences. He has published over 250 peer-reviewed manuscripts, over 100 invited reviews, and multiple textbook chapters. He is actively involved in gene therapy trials for blood, immunodeficiency, and
neurological genetic diseases.
Eric P. Winer, MD
Senior Vice President for Medical Affairs and Faculty Advancement
Eric P. Winer, MD, is Dana-Farber's senior vice president for medical affairs and chief clinical strategy officer. He is chief of the Division of Women's Cancers and director of the Breast Oncology Center at
Dana-Farber/Brigham and Women's Cancer Center, and one of the leaders of the Institute's Susan F. Smith Center for Women's Cancers. In addition, he is director of the Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer and Professor
of Medicine at Harvard Medical School.
Dr. Winer's BA and MD degrees are from Yale University. He was a physician and associate professor of medicine at Duke University School of Medicine before coming to Dana-Farber in 1997.